Showing results (51-60 of 121) with videos related to
Sort By:
Pageof 13
Journal of Radiation Research|May 3, 2023
Clinical results of proton beam radiotherapy for inoperable stage III non-small cell lung cancer: a Japanese national registry studyHitoshi Tatebe, Hideyuki Harada, Keita Mori, et al.Trials|April 2, 2020
Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET studyMototsugu Shimokawa, Kaname Nosaki, Takashi Seto, et al.Lung Cancer (Amsterdam, Netherlands)|February 19, 2017
Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancerTerufumi Kato, Noriyuki Masuda, Yoichi Nakanishi, et al.Investigational New Drugs|March 26, 2024
KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancerNoboru Yamamoto, Miyako Satouchi, Toshihiko Doi, et al.BMC Cancer|February 13, 2020
A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancerYoshihiro Hattori, Yuko Kono, Shoichi Itoh, et al.Cancer Science|July 3, 2019
Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysisTomonori Hirashima, Miyako Satouchi, Toyoaki Hida, et al.Cancer Science|August 28, 2016
Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapyToyoaki Hida, Kazuhiko Nakagawa, Takashi Seto, et al.Cancer Treatment and Research Communications|February 13, 2026
Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancerKoichi Azuma, Mitsuo Osuga, Shoichi Itoh, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 28, 2025
Long-term outcomes of concurrent chemo-proton therapy for unresectable stage III non-small cell lung cancer: a Japanese national registry studyHiromitsu Iwata, Masao Murakami, Kazushi Maruo, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 11, 2011
Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancerIsamu Okamoto, Hiroshige Yoshioka, Koji Takeda, et al.Pageof 13